VolitionRx Receives Sell Rating from Analysts at StockNews.com

VolitionRx (NYSE:VNRX) recently came under the spotlight as StockNews.com initiated its coverage of the company with a negative outlook. In a report released on Monday, the brokerage assigned a sell rating to the stock, indicating a cautious stance on its future performance.

In another development regarding VolitionRx, Benchmark, a well-known financial services company, reaffirmed its position on the stock by maintaining a "hold" rating. This reaffirmation came in a report issued on August 16th.

VolitionRx Price Performance Overview

As of the last trading day, VolitionRx shares opened at $0.63. The company holds a market capitalization of approximately $58.02 million, with a price-to-earnings (P/E) ratio of -1.57 and a beta value of 1.10, reflecting its volatility compared to the broader market. Over the past year, VNRX stock has experienced a low of $0.43 and a high of $1.23. The fifty-day simple moving average stands at $0.68, while the 200-day average is slightly higher at $0.69.

In its most recent quarterly earnings report, released on August 14th, VolitionRx reported an earnings per share (EPS) of ($0.08), surpassing analysts' expectations, which forecasted an EPS of ($0.09) by $0.01. The company generated revenue of $0.40 million for that quarter, a figure above the anticipated $0.34 million. Current projections from analysts suggest that VolitionRx may report an EPS of -0.31 for the ongoing financial year.

Insider Transactions Involving VolitionRx

In related news, there has been noteworthy insider activity. Director Guy Archibald Innes purchased 150,000 shares of VolitionRx stock on August 20th at an average price of $0.67 per share, totaling $100,500. Following this transaction, Innes holds 406,683 shares of VolitionRx, with a total value estimated around $272,477.61. This purchase represents no change in the director's overall ownership percentage, as he continues to hold approximately 12.80% of the company’s stock.

Institutional Interest in VolitionRx

Institutional interests in VolitionRx also appear to be changing. Ground Swell Capital LLC recently increased its stake in the company by 78.8% during the third quarter, according to the latest filings with the Securities and Exchange Commission (SEC). Following this increase, the firm now owns 45,959 shares after acquiring an additional 20,249 shares, valued at roughly $28,000. Currently, around 8.09% of VolitionRx shares are held by hedge funds and other institutional investors.

About VolitionRx Limited

VolitionRx Limited is an international company focused on innovative epigenetics. It specializes in developing blood tests aimed at diagnosing and monitoring various cancers as well as conditions like sepsis and COVID-19, both domestically and globally. The products offered by VolitionRx include Nu.Q Vet, a cancer screening solution for dogs; Nu.Q Nets for immune system monitoring; and Nu.Q Cancer for tracking disease progression and treatment response.

Conclusion

Each update and rating reflects the analysts' sentiments and market dynamics surrounding VolitionRx. Investors are advised to remain informed about market developments affecting the stock as they navigate their investment decisions.

VolitionRx, stocks, analysts